Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study
Wyler von Ballmoos MC, Reardon MJ, Williams MR, Mangi AA, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Oh JK, Qiao H, Forrest JK. Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study. Cardiovascular Revascularization Medicine 2020, 26: 12-16. PMID: 33199247, DOI: 10.1016/j.carrev.2020.11.007.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut PRO valveParavalvular regurgitationUS clinical studiesCause mortalityClinical studiesNew York Heart Association class ISelf-expanding transcatheter valveValve Academic Research ConsortiumExtreme surgical riskMild paravalvular regurgitationAcademic Research ConsortiumAortic valve replacementIndependent core laboratoryThree-Year OutcomesSelf-expanding prosthesisLong-term resultsEffective orifice areaValve thrombosisCardiovascular mortalityExcellent hemodynamicsValve replacementEchocardiographic measuresSurgical riskTranscatheter valve